Search NLS News

The manufacturing license paves the way for Anocca’s near-term path to the clinic and long-term strategy to advance franchises of precision targeted cell therapies for different cancers and covering diverse patient populations. Anocca has built validated asset franchises against valuable cancer targets including KRAS, PRAME and MAGE, with more than 40 preclinical assets in the […]

The Omega collaboration will leverage its platform technology to develop an epigenomic controller designed to enhance metabolic activity as a part of a potential new treatment approach for obesity management. The Cellarity collaboration aims to unravel novel biological drivers of MASH and will leverage Cellarity’s platform to develop a small molecule therapy against this disease. […]

Orion Corporation and Glykos Finland have entered into a research collaboration and licensing agreement to develop next-generation antibody-drug conjugates (ADCs). Under the agreement, Orion gains access to Glykos’ ADC technologies, initiating an ADC program with the potential for expansion into two additional programs in the future. Orion will be responsible for the target selection, research, […]

Life sciences companies are urged to embrace digital transformation to help them increase the speed of manufacturing to achieve a competitive advantage, enabling accelerated medicine launch and ultimately improving patient health. Digital transformation solutions accelerating product launches David Staunton, Head of Transformation, Life Sciences Manufacturing at professional services company Cognizant, outlines how digital transformation is accelerating […]

AstraZeneca has entered into a definitive agreement to acquire Gracell Biotechnologies Inc, a global clinical-stage biopharmaceutical company developing cell therapies for the treatment of cancer and autoimmune diseases. The proposed acquisition will enrich AstraZeneca’s growing pipeline of cell therapies with GC012F, a novel, clinical-stage FasTCAR-enabled BCMA and CD19 dual-targeting autologous chimeric antigen receptor T-cell (CAR-T) […]

Lipum has announced that the Board of Directors has appointed Ola Sandborgh as new Chief Executive Officer. “Ola brings with him a wealth of useful experience to lead our company and development activities. He has a solid background within immunology and has been involved in the development and commercialisation of several anti-inflammatory products. Ola will […]

We would like to thank our readers, subscribers and collaboration partners for a fruitful 2023, and we wish you all a most wonderful holiday season! 2023 has been – yet another – challenging year, but we have also seen Nordic life science companies and researchers making great progress and announcing positive updates and results. Explore […]

The power of quantum computing holds great promise for the life science industry, not least speeding up and reducing costs within drug discovery. McKinsey & Company describes quantum computing like this in one of their Insight articles (What is quantum computing? 2023): “Classic computing is built on bits while quantum computing is built on quantum […]

Trond Erik Aune, CEO of Vectron Biosolutions, describes the life science environment in Trondheim and shares his favorite spots. Describe the vibe in Trondheim for a company like yours! “In general, Trondheim is a great place to be an entrepreneur in a science-based company, with very strong academic organizations like NTNU [the Norwegian University of […]

The Novo Nordisk Foundation (NNF) is to establish a state-of-the-art research and vaccine development initiative in collaboration with the University of Copenhagen. Research at the Novo Nordisk Foundation Initiative for Vaccines and Immunity (NIVI) will focus initially on TB, influenza and Group A Streptococcus (GAS), which collectively cause more than 2.5 million deaths per year. […]